WO2010122019A1 - Resorbable and biocompatible fibre glass compositions and their uses - Google Patents
Resorbable and biocompatible fibre glass compositions and their uses Download PDFInfo
- Publication number
- WO2010122019A1 WO2010122019A1 PCT/EP2010/055192 EP2010055192W WO2010122019A1 WO 2010122019 A1 WO2010122019 A1 WO 2010122019A1 EP 2010055192 W EP2010055192 W EP 2010055192W WO 2010122019 A1 WO2010122019 A1 WO 2010122019A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- fibre
- copolymers
- poly
- lactide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/026—Ceramic or ceramic-like structures, e.g. glasses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/10—Ceramics or glasses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/127—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing fillers of phosphorus-containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/128—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
- C03C3/078—Glass compositions containing silica with 40% to 90% silica, by weight containing an oxide of a divalent metal, e.g. an oxide of zinc
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
- C03C3/089—Glass compositions containing silica with 40% to 90% silica, by weight containing boron
- C03C3/091—Glass compositions containing silica with 40% to 90% silica, by weight containing boron containing aluminium
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
- C03C3/097—Glass compositions containing silica with 40% to 90% silica, by weight containing phosphorus, niobium or tantalum
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C4/00—Compositions for glass with special properties
- C03C4/0007—Compositions for glass with special properties for biologically-compatible glass
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C2201/00—Glass compositions
- C03C2201/06—Doped silica-based glasses
- C03C2201/08—Doped silica-based glasses containing boron or halide
- C03C2201/10—Doped silica-based glasses containing boron or halide containing boron
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C2201/00—Glass compositions
- C03C2201/06—Doped silica-based glasses
- C03C2201/20—Doped silica-based glasses containing non-metals other than boron or halide
- C03C2201/28—Doped silica-based glasses containing non-metals other than boron or halide containing phosphorus
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C2213/00—Glass fibres or filaments
- C03C2213/02—Biodegradable glass fibres
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
Definitions
- the invention relates to potassium free melt derived resorbable and biocompatible glass compositions, fibre glass of such compositions and use thereof for the manufacture of medical devices, as well as to medical devices comprising such resorbable fibres.
- bioactive glass compositions are known in the field. They are able to bond to bone and soft tissue, and they may be used for stimulating tissue or bone growth in a mammalian body. Bioactive glass also typically guides the formation of new tissue, which grows within said glass. When bioactive glasses come into contact with a physiological environment, a layer of silica gel is formed on the surface of the glass. Following this reaction, calcium phosphate is deposited to this layer and finally crystallized to a hydroxyl-carbonate apatite. Due to this hydroxyl- carbonate apatite layer the resorption of the bioactive glasses is slowed down when inserted into mammalian bodies.
- Resorbable glasses are not necessarily bioactive, i.e. they do not form a hydroxyl- carbonate apatite layer on the glass surface.
- Resorbable glass compositions are used in the glass fibre industry to resolve the problem of glass fibres ending up e.g. in lungs during installation of glass fibre insulation. Disappearance of the fibres is preferably relatively fast, so that no detrimental effects are caused to the body.
- One resorbable glass composition is disclosed in EP 0 412 878. The fibres are degraded within 32 days. Such a degradation rate is, however, too fast for most medical applications, for example for screws or pins for fixing bone defects or fractures.
- EP 0 915 812 B1 and EP 1 484 292 A1 disclose biosoluble glass composition to improve occupational health and safety.
- WO 03/018496 A1 discloses antiinflammatory, wound-healing glass powder compositions.
- US 6,482,444 B1 discloses silver-containing bioactive sol-gel derived glass compositions to be used in implanted materials, for preparation of devices used for in vitro and ex vivo cell culture.
- EP0802890B1 discloses a bioactive glass composition with a large working range. Devitrification problems are circumvented by adding potassium and optionally magnesium to the glass.
- An object of the present invention is to provide a biocompatible and resorbable melt derived glass composition.
- Another object of the present invention is to provide biocompatible and resorbable glass fibre.
- a further object of the present invention is to provide a medical device.
- a still further object of the present invention is to provide use of and resorbable melt derived glass composition and fibre.
- thermocompatible and resorbable melt derived glass composition comprising:
- Li 2 O 0-1 weight-% comprising less than 0.05 weight-% potassium.
- the present invention also provides biocompatible and resorbable glass fibre manufactured from a biocompatible and resorbable melt derived glass composition of the invention.
- the present invention further provides a medical device comprising fibre of the invention.
- the present invention still further provides use of the biocompatible and resorbable melt derived glass composition of the invention for the manufacture of glass fibre and use of the fibres of the invention for the manufacture of a medical device.
- Figure 1 illustrates pH change in SBF dissolution tests as a function of dissolution time of fibres of different fibre compositions including a composition according to the present invention.
- Figure 2 illustrates the change of tensile strength in SBF dissolution tests as a function of dissolution time of different fibre compositions of the present invention.
- bioactive material is meant a material that has been designed to elicit or modulate biological activity.
- Bioactive material is often surface-active material that is able to chemically bond with the mammalian tissues.
- resorbable in this context means that the material is disintegrated, i.e. decomposed, upon prolonged implantation when inserted into mammalian body and when it comes into contact with a physiological environment.
- resorbable glass means silica-rich glass that does not form a hydroxyl- carbonate apatite layer on its surface when in contact with a physiological environment. Resorbable glass disappears from the body through resorption and does not significantly activate cells or cell growth during its decomposition process.
- biomaterial a material intended to interface with biological systems to evaluate, treat, augment or replace any tissue, organ or function of the body.
- biocompatibility is meant the ability of a material used in a medical device to perform safely and adequately by causing an appropriate host response in a specific location.
- resorption is meant decomposition of biomaterial because of simple dissolution.
- composite is meant a material comprising at least two different constituents, for example an organic polymer and a ceramic material, such as glass.
- melt derived glass fibre glass fibre manufactured by melting glass in a crucible at 700-1500 °C and pulling glass fibres of the molten glass through holes of the crucible, resulting in fibres with a diameter in the range of 5-300 ⁇ m (micrometers).
- an implant according to the present context comprises any kind of implant used for surgical musculoskeletal applications such as screws, plates, pins, tacks or nails for the fixation of bone fractures and/or osteotomies to immobilise the bone fragments for healing; suture anchors, tacks, screws, bolts, nails, clamps, stents and other devices for soft tissue-to-bone, soft tissue-into- bone and soft tissue-to-soft tissue fixation; as well as devices used for supporting tissue or bone healing or regeneration; or cervical wedges and lumbar cages and plates and screws for postero-lateral vertebral fusion, interbody fusion and other operations in spinal surgery.
- the medical devices are expected and designed to be biocompatible and exhibit controlled resorption in the mammalian body.
- the optimal resorption rate is directly proportional to the renewal rate of the tissue in the desired implantation location.
- a considerable proportion of the implant is preferably resorbed/decom posed within 6 to 14 weeks depending on the application, in the tissue.
- the resorption rate might be several months or even several years.
- the invention can be made use of in medical devices such as canules, catheters and stents.
- the invention can be made use of in fibre reinforced scaffolds for tissue engineering.
- the present invention provides a slowly resorbable and biocompatible fibre glass composition suitable for use in medical devices.
- Resorption of degradable glasses is a function of composition and surface to volume ratio i.e. surface erosion by physiological environment. Due to high surface to volume ratio of fibres, release of alkali and alkali earth metal ions to a physiological environment can be undesirably fast. Thus it is important to know and to be able to control the resorption rate of glass and release of alkali and alkali earth metal ions to a physiological environment.
- Bioactive fibre glasses start to react immediately when contacted with aqueous solutions by alkali exchange reactions, i.e. sodium and potassium ions in the glass are replaced by hydrogen ions from the solution.
- a rapid and high degree of dissolution will locally increase the pH of surrounding interstitial fluid, in spite of its buffering capacity, to undesirably high values.
- body fluids contain a relatively high content of sodium but a low content of potassium ions.
- rapid leaching of potassium ions from glasses is likely to have a much higher relative influence on the local body fluid composition than leaching of sodium ions, i.e. alkali metal ions are responsible for a high local detrimental pH increase and also in certain cases potassium may cause physiological problems through neurotoxic and cytotoxic effects
- Potassium plays an important role in muscle contraction and nerve transmission. Muscle and nerve cells have specialized channels for moving potassium in and out of the cell. It is well known in the art that when increased amounts of potassium is in the extracellular matrix in tissues the cells of, e.g. muscles and nerves can be damaged, i.e. can be toxic to human tissues.
- the resorption rate of the glass fibres can be easily controlled and tailor- made for diverging end applications.
- the amounts of SiO 2 and Na 2 O are important features and should be kept at quantities preferably between 60 and 70 weight-% and between 5 and 20 weight-% respectively to sustain resorbability of the glass fibre without giving rise to high amounts of released alkali metals thus preventing a detrimental or toxicological local pH peak in a physiological environment.
- the amounts of SiO 2 and Na 2 O are important features and should be kept at quantities preferably between 60 and 70 weight-% and between 5 and 20 weight-% respectively to sustain resorbability of the glass fibre without giving rise to high amounts of released alkali metals thus preventing a detrimental or toxicological local pH peak in a physiological environment.
- fibres phosphorous and calcium oxides are required in sufficient amounts.
- aluminium and boric oxide can be used to reduce solubility
- magnesium oxide can be added to increase elasticity and enhance the fibre formation from melt.
- a typical potassium free, i.e. comprising at most only minute amounts of potassium, resorbable melt derived glass composition suitable for the present invention comprises
- the glass composition is potassium free, it may include potassium, e.g. as an impurity from raw materials, but not more than 0.05 weight-%, preferably not more than 0.03 weight-%, more preferably not more than 0.01 weight-% and most preferably not more than 0.005 weight-%. Potassium is preferably excluded and should be avoided even as an impurity. Many preferred compositions of the invention comprise
- compositions of the invention comprise:
- compositions of the invention comprise SiO 2 64-66 weight-%,
- Resorbable and biocompatible melt derived glass fibres of the present invention are manufactured from resorbable glass compositions according to the invention.
- Preferred fibres according to the invention are manufactured from preferred compositions of the invention.
- the time for typical fibres of the invention to be fully resorbed in vitro in simulated body fluid (SBF), calculated using a resorption rate determined by dissolution in sink at +37 °C using the linear portion of the resorption curve, is 1 -100, preferably 2-45, more preferably 3-15, even more preferably 4-70, still more preferably 5-30 and most preferably 6-15 months. 5
- SBF simulated body fluid
- the thickness of typical fibres of the invention is ⁇ 300 ⁇ m, preferably 1 -75 ⁇ m, more preferably 5-30 ⁇ m, even more preferably 10-25 ⁇ m, still more preferably 10-20 ⁇ m and most preferably about 15 ⁇ m.
- the tensile strength of typical fibres of the invention is 0.7-3 GPa, preferably 0.9- 2.5 GPa, more preferably 1 .0-2.0 GPa and most more preferably 1 .5-2.0 GPa.
- the tensile strength of other typical fibres of the invention is 0.6-2 GPa, preferably 0.9-1.8 GPa, more preferably 1.0-1.6 GPa and most more preferably 1.1-1.5 GPa.
- Medical devices according to the invention comprise fibres of the invention.
- Preferred medical devices according to the present invention comprise preferred fibres of the invention.
- Typical medical devices of the invention are any kind of implants used within the body, preferably selected from the group consisting of a joint implant, an internal/external fixation device, a stent a, pin, a nail, a screw, a spike, a stud, a plate, and a device for supporting tissue or bone healing and/or regeneration.
- the amount of fibre according to the invention is > 10 volume-%, preferably > 40 volume-%, more preferably > 60 volume-%, most preferably > 90 volume-% of the total volume of the fibres of said medical device.
- the fibres are embedded in a continuous polymer matrix.
- the polymer matrix comprises at least one polymer selected from the group consisting of polyglycolide (PGA); copolymers of glycolide, such as glycolide/L-lactide copolymers (PGA/PLLA), glycolide/tri- methylene carbonate copolymers (PGA/TMC); polylactides (PLA); stereocopolymers of PLA, such as poly-L-lactide (PLLA), poly-DL-lactide (PDLLA), L-lactide/DL-lactide copolymers; other copolymers of PLA, such as lactide/tetramethylglycolide copolymers, lactide/trimethylene carbonate copoly- mers, lactide/d-valerolactone copolymers, lactide/ ⁇ -caprolactone copolymers; terpolymers of PLA, such as lactide/glycolide/trimethylene carbonate
- Fibres as such or comprised in the medical devices are resorbable and biocompatible when exposed to a physiological environment.
- the above mentioned glass compositions are manufactured according to a standard melt processes known in the art, except for a certain limitation that is included in the fibre glass manufacturing process. Special focus is required on raw material purity, particle size distribution, homogeneity derived from the sequence of melting, crushing and re-melting process. A homogeneous glass preform, manufactured by the melt process, is then drawn to fibre according to process described in patent application EP1958925A1. Because resorbable and bioactive glasses have a strong tendency to transfer from the amorphous glass state to the crystalline state when heating glass proprietary technology, e.g. technology disclosed in patent application EP1958925A1 enabling the manufacture of a wide range of resorbable and bioactive glasses circumventing problems relating to crystallization during fibre production, to produce fibres is preferably used.
- suitable glass fibres normally show a tensile strength of 700 MPa-3 GPa, more typically 900 MPa- 2.5 GPa, preferably 1.0-2.0 GPa, more preferably 1.5-2.0 GPa.
- Comparable polymer fibres have typically a tensile strength of 300-600 MPa.
- Modulus for glass fibres is typically 50-100 GPa, more typically 60-80 GPa, preferably 65-75 GPa.
- the advantage of the medical devices according to the present invention is that they disappear from the body by degradation without giving rise to toxic effects through the release of potassium and/or a high local pH.
- a medical device according to the present invention can be manufactured by arranging the fibres with a polymer matrix, preferably with a resorbable polymer matrix, and using any type of polymer processing equipment, e.g. open or closed batch mixer or kneader, continuous stirring tank reactor or mixer, extruder, injection moulding machine, RIM, tube reactor or other standard melt processing or melt mixing equipment known in the field, producing and/or shaping the arranged fibres with the polymer matrix into an implant having a desired orientation of the continuous fibres and/or chopped/cut fibres and/or woven, non-woven mats/textiles.
- any type of polymer processing equipment e.g. open or closed batch mixer or kneader, continuous stirring tank reactor or mixer, extruder, injection moulding machine, RIM, tube reactor or other standard melt processing or melt mixing equipment known in the field, producing and/or shaping the arranged fibres with the polymer matrix into an implant having a desired orientation of the continuous fibres and/or chopped/cut fibres and/or
- the melting temperature of the matrix material is around 30-300 °C, and the glass transition temperature of the fibres around 450-650 °C. Consequently, the glass fibres are not damaged by the temperature of the melted matrix material and a strong fibre reinforced medical device is obtained when the matrix is let to solidify.
- the implants according to the present invention can also be manufactured by using any type of polymer processing equipment, e.g. open or closed batch mixer or kneader, continuous stirring tank reactor or mixer, extruder, injection molding machine, RIM, tube reactor, or other standard melt processing or melt mixing equipment known in the field.
- the glass composition according to the present invention is, in addition to being resorbable, also biocompatible. It can thus be implanted in mammals, such as humans, and it does not react in an undesirable manner, cause any side effects or reject the surrounding tissues.
- the resorption rate of the resorbable glass composition according to the present invention is normally 1-100, 3-30, 4-80, 5-45, 6-20, sometimes 8-16 months, which resorption rates are sufficient for medical applications.
- a typical resorption rate for an anterior cruciate ligament screw is 3-24 months, the silica content of the composition then being approximately from 60 to 65 weight-%.
- the typical resorption rate is 12-24 months when the composition is used for medical devices suitable for internal fixation devices, the silica content of the composition then being approximately from 66 to 70 weight-%.
- the resorption rate or degradation can be measured by measuring the silica ion concentration dissolved at certain immersion times in aqueous solution.
- a method suitable for measuring resorption rates, i.e. glass fibre disintegration, is disclosed for example in J. Korventausta et al., Biomatehals, Vol. 24, Issue 28, December 2003, pp. 5173 - 5182.
- Another way to measure degradation is to monitor weight loss, pH change and mechanical strength loss in aqueous solution.
- the present invention also relates to resorbable and biocompatible glass fibres manufactured from resorbable and biocompatible glass compositions as defined above. All the features and embodiments listed above in connection with the suitable resorbable and biocompatible glass compositions apply mutatis mutandis to the suitable fibres and to the medical devices according to the present invention.
- the thickness of the fibres suitable for the present invention is ⁇ 300 ⁇ m, typically 1-75 ⁇ m, more typically 5-30 ⁇ m, preferably 10-25 ⁇ m, more preferably 10-20 ⁇ m, usually approximately 15 ⁇ m.
- the fibres can be used as long single fibres, as yarns, braids, ravings, and bands or as different types of fabrics made by using the methods of textile technology.
- the fibres can also be used as chopped fibres and mats or textiles manufactured from chopped fibre.
- fibres having a diameter ⁇ 300 ⁇ m, typically 1-75 ⁇ m, more typically 5-30 ⁇ m, preferably 10-25 ⁇ m, more preferably 10-20 ⁇ m, usually approximately 15 ⁇ m can be used as chopped fibres.
- Chopped fibres can be used also for preparing non-woven textile-like materials. These non-woven textiles can be combined with resorbable plastics and can be used for example for the manufacture of hot moulded implants. Chopped fibres can also be used to reinforce implants that are manufactured by injection moulding or other processing techniques known in the field of polymer processing.
- the length of the chopped fibres is ⁇ 20 mm, typically 0.5-10 mm, more typically 1-5 mm, preferably 3-5 mm, usually approximately 5 mm.
- the length of the continuous fibres is > 20 mm, preferably > 30 mm, usually more than 40 mm or most preferably as fully continuous fibre in pultrusion as an example.
- the resorbable glass composition suitable for the present invention can be used for manufacturing various medical devices. Such devices can be used to support and strengthen the defect site during healing, and can form part of the tissue once the defect is healed. Due to the long term bioactivity of some of the compositions mentioned above the tissue may grow within the resorbable material and function as a tissue regenerating scaffold.
- the medical device according to the present invention comprises a polymer matrix, preferably a continuous polymer matrix, but not excluding discontinuous polymer matrix, which polymer matrix is naturally biocompatible.
- Said biocompatible polymer matrix may be and preferably is also resorbable, however not excluding biostable biocompatible polymers.
- the resorbable glass fibres are preferably embedded in a continuous polymer matrix, which means that the surfaces of the fibres are covered by said polymer.
- a continuous polymer matrix which means that the surfaces of the fibres are covered by said polymer.
- at least 80 % of the surfaces of the fibres are covered by the polymer matrix, more preferably at least 90 %, and most preferably at least 95 % of the surface of the fibres is covered by the polymer matrix.
- Preferably also at least 99 % of the fibres of the surface of the medical device are covered by the polymer matrix.
- the fibres can be used as load bearing component embedded a degradable matrix in a tissue engineering medical device with or without higher bioactivity and resorption rate containing degradable glass, which can be in form of granules, spheres, blocks and fibres.
- the fibres can be used as a bioactive component embedded in a degradable matrix in a porous tissue engineering scaffold.
- the scaffold has a porosity degree of 60 %, more preferably at least 80 %, and most preferably at least 90 %.
- the polymer matrix material of the medical device according to the present invention may be selected from the group consisting of biocompatible polymers, such as polymers of methacrylic acid, acrylic acid and vinylpyrrolidone, polyolefins, polyalkylene oxides, polyvinylalcohol, polylactones, polycarbonates, poly- anhydrides, aliphatic polyesters, polyamides, polyimides, liquid crystal polymers, polyorthoesters, copolymers of the above mentioned and thermosets of above mentioned polymers, polymers and copolymers based on units derived from hydroxyacids and natural polymers, such as sugars, starch, cellulose and cellulose derivatives, polysaccharides, collagen, chitosan, fibrin, hyalyronic acid, polypeptides and proteins.
- biocompatible polymers such as polymers of methacrylic acid, acrylic acid and vinylpyrrolidone, polyolefins, polyalkylene oxides, polyvinylalcohol, poly
- the polymer matrix material may thus be either a biostable or a resorbable material.
- the material can be porous or it can become porous during the use and/or when in contact with the tissue.
- Biostable polymers do not dissolve or react in contact with body fluids or tissue.
- Some suitable biostable polymers are derivatives of acrylic acid or methacrylic acid, such as methyl(methacrylate).
- Some suitable resorbable polymers are homo- and copolymers of lactones and lactides and polycarbonates.
- the polymer may be a biodegradable and/or bioresorbable polymer and/or a biopolymer, preferably derived from hydroxyl acid units, a preferred polymeric material being poly( ⁇ -caprolactone-l-lactide) copolymer or poly( ⁇ -caprolactone) or poly(dl-lactide) or poly(l-lactide) or poly(l-lactide-co- glycolide).
- Mixtures of any of the above-mentioned polymers and their various forms may also be used. For some embodiments also gutta-percha may be used.
- polyglycolide polyglycolide
- PGA polyglycolide
- PGA/TMC copolymers of glycolide, glycolide/thmethylene carbonate copolymers
- PLA other copolymers of PLA, such as lactide/tetramethylglycolide copolymers, lactide/trimethylene carbonate copolymers, lactide/d-valerolactone copolymers, lactide/ ⁇ -caprolactone copolymers
- terpolymers of PLA such as lactide/gly- colide/trimethylene carbonate terpolymers, lactide/glycolide/ ⁇ -caprolactone terpolymers, PLA/polyethylene oxide copolymers
- polydepsipeptides unsymmetri- cally 3,6-substituted poly-1 ,4-dioxane-2,5-diones
- polyhydroxyalkanoates polyglycolide
- the medical device according to the present invention may also comprise bioactive glass fibres, such as fibres made of compositions disclosed in EP 080 2890 and EP 1405 647.
- the medical device may also comprise polymer fibres, such as fibres of any of the polymers mentioned above in connection with the polymer matrix.
- the amount of resorbable glass fibres is usually > 10 volume-%, preferably > 40 volume-%, more preferably > 60 volume-%, most preferably > 90 volume-% of the total volume of the fibres of the medical device.
- the medical device may comprise two or more types of resorbable fibres, each type having a different composition.
- the medical device may also comprise two or more groups of fibres having different median diameter. It is also possible that all of the fibres of the medical device do not have the same diameter, but the diameter may vary as desired.
- All the fibres used in the medical devices according to the present invention may be in various forms such as continuous fibres or chopped fibres. Their orientation can also be freely chosen depending on the medical device in which they are used and in function of the intended use.
- biodegradable glass preform was made according to the following procedure: dry-mix of raw materials, melting in pt-crucible in furnace, annealing, crushing, re-melting and annealing from following raw material sources: SiO 2 , AI 2 O 3 , Na 2 CO 3 , (CaHPO 4 )(H 2 O), CaCO 3 , H 3 BO 3 and MgO.
- Fibre drawing was conducted according to method in patent application EP1958925A1.
- compositions were used for preform and fibre manufacturing for a pH study:
- the average fibre diameter was deducted to 35 ⁇ m by SEM images of fibre cross sections. Cut (16 mg) fibres were immersed in 1 6 ml simulated body fluid [SBF by Kokubo et.al. J.Biomed. Mater. Res. 24 (1990), p.72], i.e. under in sink conditions. These values gave roughly the surface area to the volume of SBF ratio 0.4 cm "1 .
- the immersion time intervals used were between 4 and 72 hours.
- the samples were kept in a water bath at 37 °C. After separating the samples from the SBF, the final pH of the solution was measured and the pH change during first 72 h is shown in Figure 1 .
- a fast resorbable potassium containing fibre glass composition 1 -98, presented above in example 1 was tested in w ⁇ ro with human adipose stem cells cultured in DMEM-F12 supplemented with 10 % foetal bovine serum (FBS), 1 % antibiotic/antimocotic and 1 % L-glutamine at 37 °C in a humidified 5 % CO 2 atmosphere. Before combining fibre glass 1 -98 and cells, the fibre glass was first washed three times with the cell growth medium and then incubated with cell growth medium for 48 hours. Cell viability was tested using a non-quantitative dead/alive staining method.
- FBS foetal bovine serum
- the result of cell viability testing was the following: - a notable and rapid increase of cell growth medium pH
- the composition and amorphous nature was confirmed using XRF and XRD, respectively.
- the average fibre diameter was around 35 ⁇ m.
- the composition and amorphous nature was confirmed using XRF and XRD, respectively.
- the average fibre diameter was around 35 ⁇ m.
- composition was manufactured for preform and fibre manufacturing:
- melt viscosity was measured with high temperature rotational viscometer for selected resorbable and biocompatible potassium free glass fibre compositions:
- NC-02 1 1. 0 0 2.0 18.0 2. 0 0 5 64.0 2. 5
- NC-021 1 1. 0 0 2.0 18.0 2. 0 0 64.5 2. 5
- compositions were used for preform and fibre manufacturing:
- Resorption of glass fibres were measured by loss of mechanical strength in SBF dissolution. Dissolution study was performed by immersing the fibres to SBF and the samples were withdrawn from after 0, 7 and 14 days and analysed. The tensile testing of fibres was done according to the ASTM C 1557-03 standard. The tensile strength is calculated from the ratio of the peak force and the cross-sectional area of the fibre.
- compositions, fibres, medical devices and uses of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the expert skilled in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010241006A AU2010241006B9 (en) | 2009-04-23 | 2010-04-20 | Resorbable and biocompatible fibre glass compositions and their uses |
US13/265,832 US20120040002A1 (en) | 2009-04-23 | 2010-04-20 | Resorbable and biocompatible fibre glass compositions and their uses |
CN2010800178875A CN102421716A (en) | 2009-04-23 | 2010-04-20 | Resorbable and biocompatible fibre glass compositions and their uses |
EP10715532A EP2421803A1 (en) | 2009-04-23 | 2010-04-20 | Resorbable and biocompatible fibre glass compositions and their uses |
RU2011147379/03A RU2558101C2 (en) | 2009-04-23 | 2010-04-20 | Resorbable and biocompatible glass fibre compositions and use thereof |
BRPI1013728A BRPI1013728B8 (en) | 2009-04-23 | 2010-04-20 | biocompatible and absorbable fiberglass compositions and their uses |
CA2756395A CA2756395C (en) | 2009-04-23 | 2010-04-20 | Resorbable and biocompatible fibre glass compositions and their uses |
JP2012506468A JP5689870B2 (en) | 2009-04-23 | 2010-04-20 | Absorbable and biocompatible fiberglass compositions and their use |
KR1020117024651A KR101742017B1 (en) | 2009-04-23 | 2010-04-20 | Resorbable and biocompatible fibre glass compositions and their uses |
IL215181A IL215181A0 (en) | 2009-04-23 | 2011-09-15 | Resorbable and biocompatible fibre glass compositions and their uses |
US14/245,071 US9381277B2 (en) | 2009-04-23 | 2014-04-04 | Resorbable and biocompatible fibre glass compositions and their uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09158608.1A EP2243749B1 (en) | 2009-04-23 | 2009-04-23 | Resorbable and biocompatible fibre glass compositions and their uses |
EP09158608.1 | 2009-04-23 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/265,832 A-371-Of-International US20120040002A1 (en) | 2009-04-23 | 2010-04-20 | Resorbable and biocompatible fibre glass compositions and their uses |
US14/245,071 Continuation US9381277B2 (en) | 2009-04-23 | 2014-04-04 | Resorbable and biocompatible fibre glass compositions and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010122019A1 true WO2010122019A1 (en) | 2010-10-28 |
Family
ID=41095924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/055192 WO2010122019A1 (en) | 2009-04-23 | 2010-04-20 | Resorbable and biocompatible fibre glass compositions and their uses |
Country Status (13)
Country | Link |
---|---|
US (2) | US20120040002A1 (en) |
EP (2) | EP2243749B1 (en) |
JP (1) | JP5689870B2 (en) |
KR (1) | KR101742017B1 (en) |
CN (2) | CN105797214A (en) |
AU (1) | AU2010241006B9 (en) |
BR (1) | BRPI1013728B8 (en) |
CA (1) | CA2756395C (en) |
CO (1) | CO6440586A2 (en) |
CR (1) | CR20110516A (en) |
IL (1) | IL215181A0 (en) |
RU (1) | RU2558101C2 (en) |
WO (1) | WO2010122019A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102531385A (en) * | 2012-01-17 | 2012-07-04 | 上海中山医疗科技发展公司 | Bioactive glass and preparation method thereof |
WO2016035089A1 (en) * | 2014-09-07 | 2016-03-10 | Resorbium Ltd. | Biocomposite orthopedic implant introducer assembly |
WO2018002917A1 (en) | 2016-06-27 | 2018-01-04 | Ossio Ltd. | Fiber reinforced biocomposite medical implants with high mineral content |
WO2019049062A1 (en) | 2017-09-07 | 2019-03-14 | Ossio Ltd. | Fiber reinforced biocomposite threaded implants |
WO2019123462A1 (en) | 2017-12-20 | 2019-06-27 | Ossio Ltd. | Fiber bundle reinforced biocomposite medical implants |
EP3628249A1 (en) | 2014-12-26 | 2020-04-01 | Ossio Ltd | Continuous-fiber reinforced biocomposite medical implants |
US10869954B2 (en) | 2016-03-07 | 2020-12-22 | Ossio, Ltd. | Surface treated biocomposite material, medical implants comprising same and methods of treatment thereof |
EP3470097B1 (en) | 2017-10-16 | 2021-03-31 | Arctic Biomaterials Oy | Orthopedic bioabsorbable implants |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2243749B1 (en) * | 2009-04-23 | 2015-04-08 | PURAC Biochem BV | Resorbable and biocompatible fibre glass compositions and their uses |
WO2011005933A2 (en) * | 2009-07-10 | 2011-01-13 | Bio2 Technologies, Inc. | Devices and methods for tissue engineering |
US10525169B2 (en) | 2010-10-20 | 2020-01-07 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
US11484627B2 (en) | 2010-10-20 | 2022-11-01 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
US11291483B2 (en) | 2010-10-20 | 2022-04-05 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants |
US9320601B2 (en) | 2011-10-20 | 2016-04-26 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants |
EP2629780A4 (en) | 2010-10-20 | 2014-10-01 | 206 Ortho Inc | Implantable polymer for bone and vascular lesions |
US10525168B2 (en) | 2010-10-20 | 2020-01-07 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
US11207109B2 (en) | 2010-10-20 | 2021-12-28 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
US11058796B2 (en) | 2010-10-20 | 2021-07-13 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
CN102590255A (en) * | 2012-02-29 | 2012-07-18 | 成都中光电科技有限公司 | Method for detecting main content of glass raw material |
JP2016525379A (en) | 2013-05-23 | 2016-08-25 | 206 オーソ,インコーポレーテッド | Methods and apparatus for treating fractures and / or for reinforcing and / or augmenting bone, including the provision and use of composite implants |
RU2603717C1 (en) * | 2015-10-13 | 2016-11-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | METHOD FOR ASSESSING BIOINERTNESS OF MEDICAL IMPLANTS in vivo |
US10464849B2 (en) * | 2015-12-08 | 2019-11-05 | Edward J. A. Pope | Fast-densified ceramic matrix composite and fabrication method |
US20170342383A1 (en) | 2016-05-27 | 2017-11-30 | Corning Incorporated | Lithium disilicate glass-ceramic compositions and methods thereof |
US10647962B2 (en) * | 2016-05-27 | 2020-05-12 | Corning Incorporated | Bioactive aluminoborate glasses |
US10875806B2 (en) * | 2017-07-19 | 2020-12-29 | Corning Incorporated | Organic-inorganic composite fibers and methods thereof |
EP3717427A1 (en) | 2017-11-28 | 2020-10-07 | Corning Incorporated | High liquidus viscosity bioactive glass |
CN111405913A (en) | 2017-11-28 | 2020-07-10 | 康宁股份有限公司 | Bioactive glass compositions and dentinal hypersensitivity repair |
CN111417603B (en) | 2017-11-28 | 2023-10-31 | 康宁股份有限公司 | Bioactive borate glass and method thereof |
US10857259B2 (en) | 2017-11-28 | 2020-12-08 | Corning Incorporated | Chemically strengthened bioactive glass-ceramics |
EP3643691B1 (en) | 2018-10-24 | 2021-07-21 | Arctic Biomaterials Oy | Biodegradable, bioactive and biocompatible glass composition |
JP7264368B2 (en) * | 2019-01-29 | 2023-04-25 | 株式会社日本触媒 | Fiber reinforced material and method for producing fiber reinforced material |
JP2020162921A (en) * | 2019-03-29 | 2020-10-08 | 巨晰光纖股▲ふん▼有限公司 | Diversion support frame for ocular drainage |
CN112390528A (en) * | 2019-08-13 | 2021-02-23 | 康宁股份有限公司 | Bioactive glass compositions |
ES2935496T3 (en) * | 2019-08-21 | 2023-03-07 | Bioretec Oy | Composite material, implant comprising it, use of the composite material and method for preparing a medical device |
EP3818994A1 (en) * | 2019-11-08 | 2021-05-12 | Septodont ou Septodont SAS ou Specialites Septodont | Non-breaking filament for shaping bone and dental substitutes |
WO2023156545A1 (en) | 2022-02-16 | 2023-08-24 | Purac Biochem B.V. | Resorbable and biocompatible glass fiber bundle having a well-defined diameter and process for making such |
TW202337504A (en) | 2022-03-17 | 2023-10-01 | 巨晰光纖股份有限公司 | Biological glass fiber for regenerative medical materials and applications therefrom |
CN114796629A (en) * | 2022-04-18 | 2022-07-29 | 北京纳通医学研究院有限公司 | Absorbable bioactive suture anchor and preparation method and application thereof |
CN115671400B (en) * | 2022-10-27 | 2024-02-02 | 牛瑞瑞 | Composite absorbable implant, and preparation method and application thereof |
CN116036386B (en) * | 2023-02-22 | 2024-04-30 | 天津纳博特医疗器械有限公司 | Absorbable glass fiber reinforced polylactic acid composite material and craniomaxillofacial nail plate system |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0412878A1 (en) | 1989-08-11 | 1991-02-13 | Isover Saint-Gobain | Glass fibres degradable in physiological medium |
WO1996021628A1 (en) * | 1995-01-13 | 1996-07-18 | Maria Brink | Novel bioactive glasses and their use |
US6482444B1 (en) | 1999-06-14 | 2002-11-19 | Imperial College Innovations | Silver-containing, sol/gel derived bioglass compositions |
WO2003018496A1 (en) | 2001-08-22 | 2003-03-06 | Schott Glas | Antimicrobial, anti-inflammatory, wound-healing glass powder and use thereof |
EP0915812B1 (en) | 1997-03-28 | 2004-03-10 | Johns Manville International, Inc. | Biosoluble pot and marble (flame attenuated)-derived fiberglass |
EP1405647A1 (en) | 2002-10-03 | 2004-04-07 | Heimo Ylänen | Bioactive glass composition |
EP1484292A1 (en) | 2002-01-23 | 2004-12-08 | Paramount Glass Manufacturing Co., Ltd. | Glass composition for preparing inorganic fiber, method for production thereof and formed product from the inorganic fiber |
US20050142077A1 (en) * | 2001-12-12 | 2005-06-30 | Jose Zimmer | Usa of an antimicrobial glass ceramic for dental care and oral hygiene |
EP1655042A1 (en) * | 2004-11-02 | 2006-05-10 | Vivoxid Oy | A medical device |
EP1958925A1 (en) | 2007-02-13 | 2008-08-20 | Vivoxid Oy | A system and method for manufacturing fibres |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658182B1 (en) * | 1990-02-09 | 1993-11-26 | Isover Saint Gobain | GLASS FIBERS LIKELY TO DECOMPOSE IN A BIOLOGICAL ENVIRONMENT. |
FR2699402B1 (en) | 1992-12-18 | 1995-02-17 | Composites Develloppement | High performance composite material especially for dental and medical use and its production process. |
US5468544A (en) * | 1993-11-15 | 1995-11-21 | The Trustees Of The University Of Pennsylvania | Composite materials using bone bioactive glass and ceramic fibers |
RU2105529C1 (en) * | 1995-06-30 | 1998-02-27 | Клиническое научно-производственное объединение "Биотехника" | Surgical device and ceramic biologically active material for using in osteosynthesis |
US5977204A (en) | 1997-04-11 | 1999-11-02 | Osteobiologics, Inc. | Biodegradable implant material comprising bioactive ceramic |
WO1998053768A1 (en) * | 1997-05-30 | 1998-12-03 | Osteobiologics, Inc. | Fiber-reinforced, porous, biodegradable implant device |
AU1194999A (en) | 1997-10-23 | 1999-05-10 | University Of Florida | Bioactive composites comprising silane functionalized polyaryl polymers |
FR2781788B1 (en) * | 1998-08-03 | 2001-08-10 | Saint Gobain Isover | COMPOSITION OF MINERAL WOOL |
EP1048625B1 (en) * | 1999-04-30 | 2004-01-02 | Poliglas, S.A. | Biosoluble composition of glass fibres for the production of glass wools and the like |
US7597900B2 (en) * | 2001-03-27 | 2009-10-06 | Schott Ag | Tissue abrasives |
EP1549359A2 (en) | 2002-10-08 | 2005-07-06 | Osteotech, Inc. | Coupling agents for orthopedic biomaterials |
FI20030780A0 (en) * | 2003-05-23 | 2003-05-23 | Bioxid Oy | Prepreg and its use |
US7617490B2 (en) | 2003-09-10 | 2009-11-10 | Intel Corporation | Methods and apparatus for dynamic best fit compilation of mixed mode instructions |
US7959940B2 (en) * | 2006-05-30 | 2011-06-14 | Advanced Cardiovascular Systems, Inc. | Polymer-bioceramic composite implantable medical devices |
FI124017B (en) * | 2006-06-30 | 2014-01-31 | Stick Tech Oy | Curing Fiber Reinforced Composites and Methods for Making Application Oriented Fiber Reinforced Composites |
FR2905695B1 (en) * | 2006-09-13 | 2008-10-24 | Saint Gobain Isover Sa | COMPOSITIONS FOR MINERAL WOOL |
EP2243749B1 (en) * | 2009-04-23 | 2015-04-08 | PURAC Biochem BV | Resorbable and biocompatible fibre glass compositions and their uses |
ES2379676T3 (en) * | 2009-04-23 | 2012-04-30 | Vivoxid Oy | Biocompatible composite material and its use |
-
2009
- 2009-04-23 EP EP09158608.1A patent/EP2243749B1/en active Active
-
2010
- 2010-04-20 AU AU2010241006A patent/AU2010241006B9/en active Active
- 2010-04-20 BR BRPI1013728A patent/BRPI1013728B8/en active IP Right Grant
- 2010-04-20 CN CN201610094871.3A patent/CN105797214A/en active Pending
- 2010-04-20 JP JP2012506468A patent/JP5689870B2/en active Active
- 2010-04-20 KR KR1020117024651A patent/KR101742017B1/en active IP Right Grant
- 2010-04-20 WO PCT/EP2010/055192 patent/WO2010122019A1/en active Application Filing
- 2010-04-20 CA CA2756395A patent/CA2756395C/en active Active
- 2010-04-20 US US13/265,832 patent/US20120040002A1/en not_active Abandoned
- 2010-04-20 RU RU2011147379/03A patent/RU2558101C2/en active
- 2010-04-20 CN CN2010800178875A patent/CN102421716A/en active Pending
- 2010-04-20 EP EP10715532A patent/EP2421803A1/en not_active Withdrawn
-
2011
- 2011-09-15 IL IL215181A patent/IL215181A0/en unknown
- 2011-10-03 CR CR20110516A patent/CR20110516A/en unknown
- 2011-10-18 CO CO11138645A patent/CO6440586A2/en not_active Application Discontinuation
-
2014
- 2014-04-04 US US14/245,071 patent/US9381277B2/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0412878A1 (en) | 1989-08-11 | 1991-02-13 | Isover Saint-Gobain | Glass fibres degradable in physiological medium |
WO1996021628A1 (en) * | 1995-01-13 | 1996-07-18 | Maria Brink | Novel bioactive glasses and their use |
EP0802890A1 (en) | 1995-01-13 | 1997-10-29 | Maria Brink | Novel bioactive glasses and their use |
EP0802890B1 (en) | 1995-01-13 | 2001-09-19 | Maria Brink | Novel bioactive glasses and their use |
EP0915812B1 (en) | 1997-03-28 | 2004-03-10 | Johns Manville International, Inc. | Biosoluble pot and marble (flame attenuated)-derived fiberglass |
US6482444B1 (en) | 1999-06-14 | 2002-11-19 | Imperial College Innovations | Silver-containing, sol/gel derived bioglass compositions |
WO2003018496A1 (en) | 2001-08-22 | 2003-03-06 | Schott Glas | Antimicrobial, anti-inflammatory, wound-healing glass powder and use thereof |
US20050142077A1 (en) * | 2001-12-12 | 2005-06-30 | Jose Zimmer | Usa of an antimicrobial glass ceramic for dental care and oral hygiene |
EP1484292A1 (en) | 2002-01-23 | 2004-12-08 | Paramount Glass Manufacturing Co., Ltd. | Glass composition for preparing inorganic fiber, method for production thereof and formed product from the inorganic fiber |
EP1405647A1 (en) | 2002-10-03 | 2004-04-07 | Heimo Ylänen | Bioactive glass composition |
EP1655042A1 (en) * | 2004-11-02 | 2006-05-10 | Vivoxid Oy | A medical device |
EP1958925A1 (en) | 2007-02-13 | 2008-08-20 | Vivoxid Oy | A system and method for manufacturing fibres |
Non-Patent Citations (6)
Title |
---|
"Definitions in biomaterials: Proceedings of a consensus conference of the European Society for Biomaterials", 3 March 1986, ELSEVIER |
J. KORVENTAUSTA ET AL., BIOMATERIALS, vol. 24, no. 28, December 2003 (2003-12-01), pages 5173 - 5182 |
KELLOMAKI M ET AL: "Bioabsorbable scaffolds for guided bone regeneration and generation", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 24, 15 December 2000 (2000-12-15), pages 2495 - 2505, XP004217413, ISSN: 0142-9612 * |
KOKUBO, J.BIOMED. MATER. RES., vol. 24, 1990, pages 72 |
See also references of EP2421803A1 |
WILLIAMS DF; BLACK J; DOHERTY PJ: "Biomaterial-Tissue Interfaces", 1992, ELSEVIER, article "Second consensus conference on definitions in biomaterials" |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102531385A (en) * | 2012-01-17 | 2012-07-04 | 上海中山医疗科技发展公司 | Bioactive glass and preparation method thereof |
WO2016035089A1 (en) * | 2014-09-07 | 2016-03-10 | Resorbium Ltd. | Biocomposite orthopedic implant introducer assembly |
US10869708B2 (en) | 2014-09-07 | 2020-12-22 | Ossio, Ltd. | Anisotropic biocomposite material, medical implants comprising same and methods of treatment thereof |
US11678923B2 (en) | 2014-09-07 | 2023-06-20 | Ossio, Ltd. | Anisotropic biocomposite material, medical implants comprising same and methods of treatment thereof |
US11730866B2 (en) | 2014-12-26 | 2023-08-22 | Ossio, Ltd. | Continuous-fiber reinforced biocomposite medical implants |
EP3628249A1 (en) | 2014-12-26 | 2020-04-01 | Ossio Ltd | Continuous-fiber reinforced biocomposite medical implants |
US10926004B2 (en) | 2014-12-26 | 2021-02-23 | Ossio Ltd. | Continuous-fiber reinforced biocomposite medical implants |
US10869954B2 (en) | 2016-03-07 | 2020-12-22 | Ossio, Ltd. | Surface treated biocomposite material, medical implants comprising same and methods of treatment thereof |
US11491264B2 (en) | 2016-06-27 | 2022-11-08 | Ossio Ltd. | Fiber reinforced biocomposite medical implants with high mineral content |
WO2018002917A1 (en) | 2016-06-27 | 2018-01-04 | Ossio Ltd. | Fiber reinforced biocomposite medical implants with high mineral content |
WO2019049062A1 (en) | 2017-09-07 | 2019-03-14 | Ossio Ltd. | Fiber reinforced biocomposite threaded implants |
EP3470097B1 (en) | 2017-10-16 | 2021-03-31 | Arctic Biomaterials Oy | Orthopedic bioabsorbable implants |
US11813007B2 (en) | 2017-10-16 | 2023-11-14 | Arctic Biomaterials Oy | Orthopedic bioabsorbable implants |
WO2019123462A1 (en) | 2017-12-20 | 2019-06-27 | Ossio Ltd. | Fiber bundle reinforced biocomposite medical implants |
Also Published As
Publication number | Publication date |
---|---|
US9381277B2 (en) | 2016-07-05 |
JP5689870B2 (en) | 2015-03-25 |
JP2012524705A (en) | 2012-10-18 |
IL215181A0 (en) | 2011-12-29 |
BRPI1013728A2 (en) | 2016-04-05 |
AU2010241006B9 (en) | 2014-10-02 |
US20140220338A1 (en) | 2014-08-07 |
KR20120026036A (en) | 2012-03-16 |
BRPI1013728B8 (en) | 2021-07-27 |
KR101742017B1 (en) | 2017-05-31 |
RU2011147379A (en) | 2013-05-27 |
AU2010241006B2 (en) | 2014-04-10 |
RU2558101C2 (en) | 2015-07-27 |
EP2421803A1 (en) | 2012-02-29 |
EP2243749A1 (en) | 2010-10-27 |
EP2243749B1 (en) | 2015-04-08 |
CN102421716A (en) | 2012-04-18 |
US20120040002A1 (en) | 2012-02-16 |
CO6440586A2 (en) | 2012-05-15 |
CN105797214A (en) | 2016-07-27 |
AU2010241006A1 (en) | 2011-10-13 |
BRPI1013728B1 (en) | 2021-04-06 |
CR20110516A (en) | 2012-01-19 |
CA2756395A1 (en) | 2010-10-28 |
CA2756395C (en) | 2017-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9381277B2 (en) | Resorbable and biocompatible fibre glass compositions and their uses | |
Kitsugi et al. | Bone bonding behavior of MgO CaO SiO2 P2O5 CaF2 glass (mother glass of A· W‐glass‐ceramics) | |
Kitsugi et al. | Bone bonding behavior of three kinds of apatite containing glass ceramics | |
FI117963B (en) | Material that replaces bone | |
JPH075335B2 (en) | Bioabsorbable glass fibers used to reinforce bioabsorbable polymers for bone anchors and artificial ligaments | |
AU2010240904A1 (en) | Biocompatible composite and its use | |
So et al. | Accelerated degradation and improved bone-bonding ability of hydroxyapatite ceramics by the addition of glass | |
Ali et al. | Novel biodegradable hybrid composite of polylactic acid (PLA) matrix reinforced by bioactive glass (BG) fibres and magnesium (Mg) wires for orthopaedic application | |
US20240050623A1 (en) | An implant comprising magnesium alloy and a method for preparing thereof | |
JP2019535338A (en) | Bone implant | |
Wang et al. | Mechanical and degradative properties of PLDLA biodegradable pins with bioactive glass fibers in a beagle model | |
Huttunen et al. | Fiber-reinforced bioactive and bioabsorbable hybrid composites | |
ES2893241T3 (en) | Biodegradable, bioactive and biocompatible glass composition | |
Zaffe et al. | Study on short-term implants of a fluorinated glass in bone | |
Ghimire | In vitro and mechanical properties of bioactive-glass/polymer composites | |
Jalava | In vitro bioactivity profile analysis and evaluation of usability of bioactive glass fibers as a structural part in load-bearing implants | |
Ahmed et al. | Biodegradable composite materials as bone regenerative implants | |
Wnek et al. | Bioactive Glass/Marivalda M. Pereira, Larry L. Hench |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080017887.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10715532 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2010241006 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2756395 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000516 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 2010241006 Country of ref document: AU Date of ref document: 20100420 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11138645 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 20117024651 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7641/CHENP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012506468 Country of ref document: JP Ref document number: 13265832 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010715532 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011147379 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1013728 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1013728 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111021 |